EBITDA: Income before interest, taxes, depreciation and amortization.
SpyGlass Pharma, Inc. (SGP) had EBITDA of $-40.84M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-39.87M |
|
-- |
|
-- |
|
$41.45M |
|
$-41.45M |
|
$1.58M |
|
$-39.87M |
|
$-39.87M |
|
$-39.87M |
|
$-39.87M |
|
$-39.87M |
|
$-39.87M |
|
$-41.45M |
|
|
EBITDA |
$-40.84M |
2.22M |
|
2.22M |
|
$-17.98 |
|
$-17.98 |
|
| Balance Sheet Financials | |
$108.77M |
|
$2.34M |
|
$7.10M |
|
$115.87M |
|
$8.58M |
|
-- |
|
$206.12M |
|
$214.70M |
|
$-98.84M |
|
$-98.84M |
|
$-98.84M |
|
2.20M |
|
| Cash Flow Statement Financials | |
$-32.70M |
|
$-11.79M |
|
$124.58M |
|
$16.27M |
|
$96.36M |
|
$80.09M |
|
$2.79M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.67 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-33.49M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
40.34% |
|
40.34% |
|
-34.41% |
|
40.34% |
|
$-44.84 |
|
$-15.11 |
|
$-14.75 |
|